Simris Group AB has announced the appointment of Dr. Alexis Roberts-McIntosh, a highly experienced pharmaceutical industry executive, to the position of Group CEO. Alexis Roberts-McIntosh replaces current CEO Julian Read, who will be retained as an Advisor for a handover period of 3 months. Julian Read steps back from the Company in order to pursue other opportunities and will ensure a seamless transfer of knowledge to Alexis Roberts-McIntosh during the handover period.

Dr. Roberts-McIntosh's appointment is an integral part of the strategic turnaround of the Simris Group's activities, which is underpinned by the shift in focus of the company from the low-margin and highly competitive dietary supplement space to the high-margin ADC payload pharmaceutical space - where the company's product has a sustainable competitive advantage underpinned by its broad patent protection. In the last 22 months considerable work has been done by outgoing CEO, Julian Read, to redefine Simris' corporate objectives, complete the acquisition of Cyano Biotech GmbH (since renamed Simris Biologics), and bring the Group substantially closer to securing its first ADC license agreement with a drug developer. These actions, combined with the funding support received from Simris Chairman Steven Schapera and other strategic shareholders, ensures that Dr. Roberts- McIntosh inherits a company that has a clear strategy, is operating efficiently, and is funded appropriately.

Dr. Roberts-McIntosh holds a Ph.D in Medicinal Chemistry. She began her career with GlaxoSmithKline and has since spent the last 27 years transitioning upward through ever-more senior appointments at some of world's most iconic pharmaceutical companies including Pfizer, Johnson & Johnson, Reckitt Benckiser, and Abbott. She is highly entrepreneurial, has an unblemished record of driving innovative products to commercialisation, and has managed complex teams and large P&L's. By any measure, Alexis is an accomplished leader with a proven history of delivering outstanding sales growth with accompanying profitability.